Bharati R Dhruva
Examiner (ID: 3913)
Most Active Art Unit | 1632 |
Art Unit(s) | 1632 |
Total Applications | 2 |
Issued Applications | 1 |
Pending Applications | 1 |
Abandoned Applications | 0 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17170314
[patent_doc_number] => 20210323984
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS
[patent_app_type] => utility
[patent_app_number] => 17/222442
[patent_app_country] => US
[patent_app_date] => 2021-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9212
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222442
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/222442 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | Apr 4, 2021 | Issued |
Array
(
[id] => 17141968
[patent_doc_number] => 20210309980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => ENGINEERED CHIMERIC NUCLEIC ACID GUIDED NUCLEASE CONSTRUCTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/212484
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14545
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212484
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/212484 | ENGINEERED CHIMERIC NUCLEIC ACID GUIDED NUCLEASE CONSTRUCTS AND USES THEREOF | Mar 24, 2021 | Pending |
Array
(
[id] => 17083389
[patent_doc_number] => 20210278395
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => HUMAN TROPHOBLAST STEM CELLS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/201036
[patent_app_country] => US
[patent_app_date] => 2021-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17201036
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/201036 | Human trophoblast stem cells and uses thereof | Mar 14, 2021 | Issued |
Array
(
[id] => 16868452
[patent_doc_number] => 20210161919
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => Metakaryocidal Treatments
[patent_app_type] => utility
[patent_app_number] => 17/175117
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10606
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175117
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/175117 | Metakaryocidal Treatments | Feb 11, 2021 | Pending |
Array
(
[id] => 17052546
[patent_doc_number] => 20210261980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => RECOMBINANT NUCLEIC ACID CONSTRUCT
[patent_app_type] => utility
[patent_app_number] => 17/173109
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32213
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17173109
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/173109 | RECOMBINANT NUCLEIC ACID CONSTRUCT | Feb 9, 2021 | Pending |
Array
(
[id] => 17185446
[patent_doc_number] => 20210332331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => Adeno-Associated-Virus Rep Sequences, Vectors and Viruses
[patent_app_type] => utility
[patent_app_number] => 17/167743
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30648
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17167743
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/167743 | Adeno-Associated-Virus Rep Sequences, Vectors and Viruses | Feb 3, 2021 | Pending |
Array
(
[id] => 19458557
[patent_doc_number] => 12099042
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-24
[patent_title] => Use of liquid chromatography and mass spectrometry to characterize oligonucleotides
[patent_app_type] => utility
[patent_app_number] => 17/161803
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 28
[patent_no_of_words] => 17828
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 195
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161803
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/161803 | USE OF LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY TO CHARACTERIZE OLIGONUCLEOTIDES | Jan 28, 2021 | Pending |
Array
(
[id] => 19121206
[patent_doc_number] => 11965177
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-23
[patent_title] => Method of manufacturing dual specific T-cells for use in cancer immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/160952
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 9
[patent_no_of_words] => 13250
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17160952
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/160952 | Method of manufacturing dual specific T-cells for use in cancer immunotherapy | Jan 27, 2021 | Issued |
Array
(
[id] => 17065678
[patent_doc_number] => 20210267893
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => ARTIFICIAL EXOSOME COMPOSITION AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 17/154050
[patent_app_country] => US
[patent_app_date] => 2021-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154050
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/154050 | Artificial exosome composition and related methods | Jan 20, 2021 | Issued |
Array
(
[id] => 16948405
[patent_doc_number] => 20210207096
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => Transgenic Macrophages, Chimeric Antigen Receptors, and Associated Methods
[patent_app_type] => utility
[patent_app_number] => 17/146024
[patent_app_country] => US
[patent_app_date] => 2021-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17146024
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/146024 | Transgenic macrophages, chimeric antigen receptors, and associated methods | Jan 10, 2021 | Issued |
Array
(
[id] => 19339463
[patent_doc_number] => 12049644
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Platform for generating safe cell therapeutics
[patent_app_type] => utility
[patent_app_number] => 17/145848
[patent_app_country] => US
[patent_app_date] => 2021-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 87
[patent_no_of_words] => 26788
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17145848
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/145848 | Platform for generating safe cell therapeutics | Jan 10, 2021 | Issued |
Array
(
[id] => 18994657
[patent_doc_number] => 11911474
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Delivery and formulation of engineered nucleic acids
[patent_app_type] => utility
[patent_app_number] => 17/141753
[patent_app_country] => US
[patent_app_date] => 2021-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 25
[patent_no_of_words] => 44883
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17141753
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/141753 | Delivery and formulation of engineered nucleic acids | Jan 4, 2021 | Issued |
Array
(
[id] => 19273264
[patent_doc_number] => 12023371
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Terminally modified RNA
[patent_app_type] => utility
[patent_app_number] => 17/127435
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 149430
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127435
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127435 | Terminally modified RNA | Dec 17, 2020 | Issued |
Array
(
[id] => 19209565
[patent_doc_number] => 11998601
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Messenger RNA therapy for treatment of articular disease
[patent_app_type] => utility
[patent_app_number] => 17/117981
[patent_app_country] => US
[patent_app_date] => 2020-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 12
[patent_no_of_words] => 12708
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117981
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/117981 | Messenger RNA therapy for treatment of articular disease | Dec 9, 2020 | Issued |
Array
(
[id] => 19374111
[patent_doc_number] => 12065661
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-20
[patent_title] => Genetic modification of rats
[patent_app_type] => utility
[patent_app_number] => 17/117661
[patent_app_country] => US
[patent_app_date] => 2020-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 28
[patent_no_of_words] => 34494
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117661
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/117661 | Genetic modification of rats | Dec 9, 2020 | Issued |
Array
(
[id] => 18718141
[patent_doc_number] => 11795476
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others
[patent_app_type] => utility
[patent_app_number] => 17/109018
[patent_app_country] => US
[patent_app_date] => 2020-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 22
[patent_no_of_words] => 16014
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17109018
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/109018 | AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others | Nov 30, 2020 | Issued |
Array
(
[id] => 16868493
[patent_doc_number] => 20210161960
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => CELL SUSPENSION FOR USE IN THE TREATMENT OF LOWER EXTREMITY PERIPHERAL ARTERY DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/102362
[patent_app_country] => US
[patent_app_date] => 2020-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16069
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 172
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17102362
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/102362 | CELL SUSPENSION FOR USE IN THE TREATMENT OF LOWER EXTREMITY PERIPHERAL ARTERY DISEASE | Nov 22, 2020 | Abandoned |
Array
(
[id] => 17604240
[patent_doc_number] => 11332713
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-17
[patent_title] => Gene-regulating compositions and methods for improved immunotherapy
[patent_app_type] => utility
[patent_app_number] => 16/951310
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 33
[patent_no_of_words] => 82567
[patent_no_of_claims] => 45
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951310
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/951310 | Gene-regulating compositions and methods for improved immunotherapy | Nov 17, 2020 | Issued |
Array
(
[id] => 16671414
[patent_doc_number] => 20210060177
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/099462
[patent_app_country] => US
[patent_app_date] => 2020-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17099462
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/099462 | Lipid nanoparticle compositions and methods for mRNA delivery | Nov 15, 2020 | Issued |
Array
(
[id] => 16688724
[patent_doc_number] => 20210071200
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => DELIVERY ACROSS CELL PLASMA MEMBRANES
[patent_app_type] => utility
[patent_app_number] => 17/092161
[patent_app_country] => US
[patent_app_date] => 2020-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25240
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17092161
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/092161 | Delivery across cell plasma membranes | Nov 5, 2020 | Issued |